Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease
نویسندگان
چکیده
BACKGROUND Studies on the immunotherapy for Alzheimer's disease (AD) have increasingly gained attention since 1990s. However, there are pros (preventing of AD) and cons (incurred cost and side effects) regarding the administration of immunotherapy. Up to date, there has been lacking of economic evaluation for immunotherapy of AD. We aimed to assess the cost-effectiveness analysis of the vaccination for AD. METHODS A meta-analysis of randomized control trials after systemic review was conducted to evaluate the efficacy of the vaccine. A Markov decision model was constructed and applied to a 120,000-Taiwanese cohort aged ≥65 years. Person years and quality-adjusted life years (QALY) were computed between the vaccinated group and the the unvaccinated group. Economic evaluation was performed to calculate the incremental cost-effectiveness ratio (ICER) and cost-effectiveness acceptability curve (CEAC). RESULTS Vaccinated group gained an additional 0.84 life years and 0.56 QALYs over 10-years and an additional 0.35 life years and 0.282 QALYs over 5-years of follow-up. The vaccinated group dominated the unvaccinated group by ICER over 5-years of follow-up. The ICERs of 10-year follow-up for the vaccinated group against the unvaccinated group were $13,850 per QALY and $9,038 per life year gained. Given the threshold of $20,000 of willingness to pay (WTP), the CEAC showed the probability of being cost-effective for vaccination with QALY was 70.7% and 92% for life years gained after 10-years of follow-up. The corresponding figures were 87.3% for QALY and 93.5% for life years gained over 5-years follow-up. CONCLUSION The vaccination for AD was cost-effective in gaining QALY and life years compared with no vaccination, under the condition of a reasonable threshold of WTP.
منابع مشابه
A Meta-Analysis of Efficacy and Safety of Cholinesterase Inhibitors in Mild to Moderate Alzheimer’s Disease with a Systemic Review of Quality of Life, Cost Effectiveness and Dose Delivery Preference
متن کامل
Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran
Human Papilloma Virus (HPV) vaccine recently has been added to the Iran Drug List, decision makers need information beyond that available from RCTs to recommend funding for this vaccination program to add it to the National Immunization program in Iran. Modeling and economic studies have addressed some of those information needs in foreign countries. In order to determine the long term benefit ...
متن کاملCost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran
Human Papilloma Virus (HPV) vaccine recently has been added to the Iran Drug List, decision makers need information beyond that available from RCTs to recommend funding for this vaccination program to add it to the National Immunization program in Iran. Modeling and economic studies have addressed some of those information needs in foreign countries. In order to determine the long term benefit ...
متن کاملA Pharmacoeconomic Review of Cholinesterase Inhibitor Drugs for Alzheimer’s Disease
S: Turongkaravee S. Cost utility analysis of cholinesterase inhibitors in the treatment of mild to moderate Alzheimer’s disease. Value in Health 2010;13(7):A502. Permsuwan U, Niwatananun W, Pimkrai A. Cost-utility analysis of donepezil for the treatment of Alzheimer’s disease in Thailand. Value in Health 2012;15:A648.
متن کاملCost effectiveness of influenza vaccination for specific populations in Iran
Introduction: Influenza viruses are the major respiratory pathogens worldwide and high-risk groups such as healthcare workers may develop severe forms of the disease. The purpose of this study was to evaluate the cost-effectiveness of influenza vaccination for 4 target groups including pregnant women, elderly people (aged over 65 years), healthcare workers and school-age children in Iran. Metho...
متن کامل